ECSP15026557A - Compuestos y sus métodos de empleo - Google Patents

Compuestos y sus métodos de empleo

Info

Publication number
ECSP15026557A
ECSP15026557A ECIEPI201526557A ECPI201526557A ECSP15026557A EC SP15026557 A ECSP15026557 A EC SP15026557A EC IEPI201526557 A ECIEPI201526557 A EC IEPI201526557A EC PI201526557 A ECPI201526557 A EC PI201526557A EC SP15026557 A ECSP15026557 A EC SP15026557A
Authority
EC
Ecuador
Prior art keywords
compounds
methods
inhibit glutaminase
cancer
employing
Prior art date
Application number
ECIEPI201526557A
Other languages
English (en)
Inventor
Rene M Lemieux
Jeremy Travins
Janeta Popovici-Muller
Francesco G Salituro
Jeffrey O Saunders
Yongsheng Chen
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of ECSP15026557A publication Critical patent/ECSP15026557A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se describen compuestos y composiciones que comprenden compuestos que inhiben la glutaminasa. En la presente también se describen métodos para emplear los compuestos que inhiben la glutaminasa en el tratamiento del cáncer.
ECIEPI201526557A 2012-11-22 2015-06-22 Compuestos y sus métodos de empleo ECSP15026557A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2012/085023 WO2014079011A1 (en) 2012-11-22 2012-11-22 Heterocyclic compounds for inhibiting glutaminase and their methods of use
PCT/CN2013/000294 WO2014079136A1 (en) 2012-11-22 2013-03-15 Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof

Publications (1)

Publication Number Publication Date
ECSP15026557A true ECSP15026557A (es) 2016-01-29

Family

ID=50775393

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201526557A ECSP15026557A (es) 2012-11-22 2015-06-22 Compuestos y sus métodos de empleo

Country Status (36)

Country Link
US (2) US10087172B2 (es)
EP (2) EP2922850B1 (es)
JP (2) JP6333277B2 (es)
KR (1) KR20150085079A (es)
CN (2) CN108727307A (es)
AR (1) AR093598A1 (es)
AU (2) AU2013347771B2 (es)
BR (1) BR112015011830A2 (es)
CA (1) CA2893510C (es)
CL (1) CL2015001392A1 (es)
CR (1) CR20150316A (es)
CY (1) CY1120581T1 (es)
DK (1) DK2922850T3 (es)
EA (2) EA201890754A1 (es)
EC (1) ECSP15026557A (es)
ES (1) ES2690390T3 (es)
HR (1) HRP20181628T1 (es)
HU (1) HUE040111T2 (es)
IL (1) IL238958B (es)
LT (1) LT2922850T (es)
MX (1) MX367389B (es)
MY (1) MY177344A (es)
NZ (1) NZ708382A (es)
PE (1) PE20151072A1 (es)
PH (2) PH12015501150B1 (es)
PL (1) PL2922850T3 (es)
PT (1) PT2922850T (es)
RS (1) RS57859B1 (es)
SA (1) SA515360469B1 (es)
SG (2) SG11201504049VA (es)
SI (1) SI2922850T1 (es)
SM (1) SMT201800504T1 (es)
TR (1) TR201812360T4 (es)
TW (2) TW201906825A (es)
UA (1) UA117360C2 (es)
WO (3) WO2014079011A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
PT2920168T (pt) 2012-11-16 2021-10-18 Calithera Biosciences Inc Inibidores heterocíclicos de glutaminase
CA2892089A1 (en) 2012-11-21 2014-05-30 Rene M. Lemieux Glutaminase inhibitors and methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
SG11201504184PA (en) * 2012-12-03 2015-06-29 Calithera Biosciences Inc Treatment of cancer with heterocyclic inhibitors of glutaminase
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
CA2934702A1 (en) 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Inhibitors of glutaminase
KR20160127149A (ko) 2014-03-21 2016-11-02 아지오스 파마슈티컬스 아이엔씨. 화합물 및 이의 사용 방법
WO2015166373A1 (en) * 2014-04-30 2015-11-05 Pfizer Inc. Cycloalkyl-linked diheterocycle derivatives
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CN107074805B (zh) 2014-07-03 2021-02-26 德州大学系统董事会 用于治疗疾病的gls1抑制剂
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
WO2016054388A1 (en) * 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
SG11201708153XA (en) 2015-04-06 2017-11-29 Calithera Biosciences Inc Treatment of lung cancer with inhibitors of glutaminase
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
EP3316887B1 (en) * 2015-06-30 2020-04-08 Board of Regents, The University of Texas System Gls1 inhibitors for treating disease
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
JP6971239B2 (ja) 2015-10-05 2021-11-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法
US10040789B2 (en) * 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CN106890184B (zh) * 2015-12-18 2019-06-25 诺言医药科技(上海)有限公司 抗肿瘤的谷氨酰胺酶抑制剂和肿瘤血管生成抑制剂药物组合物及其应用
BR112018012660B1 (pt) 2015-12-22 2023-12-19 Board Of Regents, The University Of Texas System Sal, solvato, ou polimorfo de um composto; polimorfo de composto sólido; composição; e uso de um sal, solvato ou polimorfo
US10278968B2 (en) * 2016-08-25 2019-05-07 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN109982703A (zh) 2016-08-25 2019-07-05 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
US10722487B2 (en) 2017-10-18 2020-07-28 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US12324807B2 (en) 2018-06-01 2025-06-10 Cornell University Combination therapy for PI3K-associated disease or disorder
US20210403479A1 (en) 2018-11-08 2021-12-30 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
US20220400732A1 (en) * 2019-03-21 2022-12-22 Cornell University Anti-fructose therapy for colorectal and small intestine cancers
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
CN112898200A (zh) * 2021-01-20 2021-06-04 都创(上海)医药科技股份有限公司 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
US4070400A (en) 1975-10-16 1978-01-24 Merck & Co., Inc. Diphenyl polyamides having a cyclohexylene moiety
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
SU1761672A1 (ru) * 1990-05-22 1992-09-15 Белгородский технологический институт строительных материалов им.И.А.Гришманова Способ получени тонкодисперсного мела
CA2155759A1 (en) 1993-03-29 1994-10-13 Bernd Janssen 1-amino-3-phenoxy propane derivatives as modulators of multi-drug resistance
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
CA2332325A1 (en) * 1998-06-18 1999-12-23 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
AU3316600A (en) 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
WO2001062206A2 (en) 2000-02-22 2001-08-30 Mount Sinai School Of Medicine Of New York University N-cadherin modulated migration, invasion, and metastasis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
DK1388734T3 (da) 2002-08-01 2004-05-03 Mtm Lab Ag Metode til opløsningsbaseret diagnose
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US20080182865A1 (en) 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
ATE477495T1 (de) 2005-03-16 2010-08-15 Osi Pharm Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
US8716472B2 (en) 2006-10-16 2014-05-06 University Of Rochester Tripodal cyclohexane derivatives and their use as carbohydrate receptors
WO2009067429A1 (en) 2007-11-19 2009-05-28 Genentech, Inc. Compositions and methods for inhibiting tumor progression
US7951549B2 (en) 2008-03-07 2011-05-31 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP3021120A1 (en) 2009-02-20 2016-05-18 Michael P. Lisanti Diagnosis, prognosis, therapeutics and methods for treating neoplastic deiseases comprising determining the level of caveolin-1 in a stromal cell sample
WO2010111504A2 (en) 2009-03-25 2010-09-30 Cornell University Inhibition of glutaminase c
WO2010120966A1 (en) 2009-04-17 2010-10-21 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US20130109643A1 (en) * 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
AU2011270968C1 (en) 2010-06-23 2017-01-19 University Of Louisville Research Foundation, Inc. Methods for detecting cancer
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
HUE047642T2 (hu) * 2011-11-21 2020-05-28 Calithera Biosciences Inc A glutamináz heterociklusos gátlói
KR20140138956A (ko) 2012-03-15 2014-12-04 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 Ｅ-카드헤린의 세포외 도메인의 저해제를 포함하는 병용 치료법
CA2892089A1 (en) 2012-11-21 2014-05-30 Rene M. Lemieux Glutaminase inhibitors and methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
WO2014138391A1 (en) 2013-03-06 2014-09-12 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
CA2934702A1 (en) 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Inhibitors of glutaminase
KR20160127149A (ko) 2014-03-21 2016-11-02 아지오스 파마슈티컬스 아이엔씨. 화합물 및 이의 사용 방법

Also Published As

Publication number Publication date
EP2922850A4 (en) 2016-05-18
US10087172B2 (en) 2018-10-02
SG10201609940RA (en) 2016-12-29
EA030646B1 (ru) 2018-09-28
PT2922850T (pt) 2018-10-15
HUE040111T2 (hu) 2019-02-28
TW201906825A (zh) 2019-02-16
CN104936954B (zh) 2018-08-14
WO2014079011A1 (en) 2014-05-30
EP3456719A1 (en) 2019-03-20
JP6333277B2 (ja) 2018-05-30
EA201590987A1 (ru) 2015-12-30
AU2013347771A1 (en) 2015-06-11
LT2922850T (lt) 2018-09-10
CA2893510C (en) 2021-01-19
PH12015501150B1 (en) 2018-05-04
CN108727307A (zh) 2018-11-02
CA2893510A1 (en) 2014-05-30
BR112015011830A2 (pt) 2017-07-11
TW201427963A (zh) 2014-07-16
SI2922850T1 (sl) 2018-10-30
CY1120581T1 (el) 2019-07-10
JP2018150316A (ja) 2018-09-27
WO2014079150A1 (en) 2014-05-30
CR20150316A (es) 2015-08-28
KR20150085079A (ko) 2015-07-22
MX2015006493A (es) 2015-08-05
TR201812360T4 (tr) 2018-09-21
EP2922850B1 (en) 2018-07-18
MY177344A (en) 2020-09-13
PH12017502141A1 (en) 2019-02-27
PL2922850T3 (pl) 2018-12-31
ES2690390T3 (es) 2018-11-20
RS57859B1 (sr) 2018-12-31
AU2013347771B2 (en) 2018-02-01
NZ708382A (en) 2020-04-24
AU2018202954A1 (en) 2018-05-17
EA201890754A1 (ru) 2018-08-31
CL2015001392A1 (es) 2016-04-22
TWI629268B (zh) 2018-07-11
JP2016500082A (ja) 2016-01-07
IL238958A0 (en) 2015-07-30
EP2922850A1 (en) 2015-09-30
SA515360469B1 (ar) 2017-07-11
AR093598A1 (es) 2015-06-10
PH12015501150A1 (en) 2015-08-17
US20150291576A1 (en) 2015-10-15
HRP20181628T1 (hr) 2018-12-14
IL238958B (en) 2019-09-26
CN104936954A (zh) 2015-09-23
SMT201800504T1 (it) 2018-11-09
US10689375B2 (en) 2020-06-23
US20190084976A1 (en) 2019-03-21
WO2014079136A1 (en) 2014-05-30
DK2922850T3 (en) 2018-10-08
SG11201504049VA (en) 2015-07-30
HK1214593A1 (en) 2016-07-29
UA117360C2 (uk) 2018-07-25
PE20151072A1 (es) 2015-08-26
MX367389B (es) 2019-08-19

Similar Documents

Publication Publication Date Title
ECSP15026557A (es) Compuestos y sus métodos de empleo
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
CL2019000511A1 (es) Inhibidores de procesos metabólicos celulares.
CR20150571A (es) Compuestos y composiciones terapéuticos
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
UY34538A (es) Heteroarilos y usos de los mismos
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2017000576A1 (es) Inhibidores de mk2 y sus usos
CL2015002194A1 (es) Inhbidores de erk y sus usos
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
MX2015003140A (es) Formulaciones de enzalutamida.
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
MX2015010312A (es) Metodos para tratamiento del melanoma.
CL2016003260A1 (es) Profármacos de gemcitabina
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CL2015001246A1 (es) Derivados de bendamustina y los metodos de su uso
MX2018010993A (es) Derivados de icariina e icaritina.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.